文献速递哮喘

londamocitinib(AZD4604)每日两次治疗12周用于中重度哮喘的2a期随机双盲安慰剂对照研究

Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA
RSS 订阅 · BMJ Open Respiratory Research

AJAX是一项2a期随机双盲安慰剂对照研究,评估吸入性JAK1抑制剂londamocitinib在中高剂量ICS-LABA控制不佳的中重度哮喘成人中的疗效、安全性和药代动力学。主要终点为首次CompEx哮喘事件时间,次要终点包括肺功能、哮喘控制、症状评分及呼出气一氧化氮等。

要点

  • londamocitinib为高效特异性吸入JAK1抑制剂,可阻断多条JAK1依赖信号通路。
  • 研究针对中高剂量ICS-LABA控制不佳的中重度哮喘成人,探索生物制剂升级前的附加治疗。
  • 主要终点为首次CompEx哮喘事件时间,次要终点涵盖肺功能、哮喘控制及气道炎症指标。

核心结论

  • 研究旨在评估londamocitinib在中重度哮喘患者中的疗效、安全性和药代动力学。

研究设计与样本

  • 2a期随机双盲部分去中心化安慰剂对照研究,纳入中高剂量ICS-LABA控制不佳的中重度哮喘成人。

关键数值与推荐

  • 主要终点为首次CompEx哮喘事件时间。
  • 次要终点包括第4周和第12周支气管舒张前FEV1、慢性气道评估测试、六项哮喘控制问卷、每日哮喘症状评分及早晚呼气峰流速较基线的变化。
  • 还将评估呼出气一氧化氮、咳嗽严重程度及第4周和第12周所有参与者的药代动力学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Introduction Asthma is a heterogeneous condition and affected individuals show variable responses to available medications. An unmet need exists for add-on therapies that target novel molecular pathways, before patients escalate to biologics. Janus kinase 1 (JAK1) is implicated in multiple inflammatory cytokine pathways critical for the pathogenesis of asthma. Londamocitinib (AZD4604) is a highly specific, inhaled, JAK1 inhibitor with high potency to block multiple JAK1-dependent signalling pathways. AJAX is a phase 2a, randomised, double-blind, partially decentralised placebo-controlled study assessing the efficacy, safety and pharmacokinetics (PK) of londamocitinib in adults with moderate-to-severe asthma uncontrolled on medium-to-high-dose inhaled corticosteroid/long-acting β 2 -agonist. Methods and analysis The primary endpoint is time to first CompEx Asthma event. Secondary endpoints include change from baseline in prebronchodilator forced expiratory volume in 1 s, chronic airways assessment test, six-item asthma control questionnaire, daily asthma symptom score, and morning and evening peak expiratory flow at weeks 4 and 12. In addition, assessment of the effect of londamocitinib on airway inflammation as measured by the fractional exhaled nitric oxide test; cough severity assessment; and the PK of londamocitinib in all participants after 4 and 12 weeks will also be evaluated. Ethics and dissemination The study has received ethical approval from the appropriate ethic committee and will be conducted in accordance with the Declaration of Helsinki, Good Clinical Practice guidelines, and all applicable regulatory requirements. All participants will provide written informed consent prior to enrolment, with procedures in place to ensure comprehension and voluntary participation. Findings will be disseminated through peer-reviewed publications and/or presentations at scientific conferences. Summary results will be posted on the trial registry and shared with participants and relevant patient groups in lay summaries.

来源:BMJ Open Respiratory Research,查看原文。版权归原作者所有。

引用

  1. BMJ Open Respiratory Research:Phase 2a randomised, double-blind, placebo-controlled study to evaluate the efficacy and safety of londamocitinib (AZD4604) two times per day for 12 weeks in adult patients with moderate-to-severe asthma uncontrolled on medium-high-dose ICS-LABA

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。